Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06094790 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT06094790 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT06094790, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
A study designed to characterize the plasma pharmacokinetic (PK) profile of CORT125134 in healthy subjects receiving once-daily oral administration of the current capsule formulation of CORT125134 for 14 days.
Interventions
- DRUG CORT125134 150 mg
- DRUG CORT125134 250 mg
- DRUG CORT125134 dose to be determined
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2017-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06094790
The ClinicalTrials.gov registry entry for NCT06094790 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CORT125134 150 mg is the first listed.
NCT06094790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06094790 about?
NCT06094790 is a clinical study titled "A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects". A study designed to characterize the plasma pharmacokinetic (PK) profile of CORT125134 in healthy subjects receiving once-daily oral administration of the current capsule formulation of CORT125134 for 14 days.
What is the current status of trial NCT06094790?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-05-18. Estimated completion is 2017-11-15.
What interventions are being tested in trial NCT06094790?
The interventions under investigation include: CORT125134 150 mg (DRUG), CORT125134 250 mg (DRUG), CORT125134 dose to be determined (DRUG).
Who is sponsoring clinical trial NCT06094790?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.